VRAX Valuation

Virax Biolabs Group Ltd

Add to Watchlist

Advanced Chart

0.989

-0.041(-3.981%)1D

Overview
Forecast
Valuation
Earnings

VRAX Relative Valuation

VRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRAX is overvalued; if below, it's undervalued.

Historical Valuation

Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 110.18 is considered Fairly compared with the five-year average of -3.55. The fair price of Virax Biolabs Group Ltd (VRAX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.99

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.79

P/B

Median3y

1.99

Median5y

2.21

-119.55

FCF Yield

Median3y

-122.75

Median5y

-122.10

Competitors Valuation Multiple

The average P/S ratio for VRAX's competitors is 19.15, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX) exhibits a P/S ratio of 108.06, which is 464.23% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VRAX.O

Virax Biolabs Group Ltd

108.06

Average P/S: 19.15

4.29M